Abstract
The practice of neuroimaging, first by SPECT and PET, and then by magnetic resonance imaging (MRI), greatly contributes to the fundamental understanding of neuroanatomical correlates of brain function. It reveals novel treatment options in disciplines such as neurology, neurosurgery, and neuropsychiatry. The new opportunities afforded by neuroimaging yield images not only of brain tissue structure of an ever-increasing power of resolution but also, and perhaps more importantly, of the basic organization of brain work. Understanding brain work requires insight into the roles of regional cerebral blood flow and energy metabolism, obtained by measures of oxygen and glucose consumption rates, neuronal network and neurotransmitter system activity, and most recently the abnormal deposition of amyloid-beta in brain tissue and the resulting abnormalities of second messenger cascades that promise to reveal the origins of neurodegeneration.
The quantification of the brain images, acquired by means of the different methods of neuroimaging, is vital to the improved understanding and interpretation of experimental and clinical findings that are reported at a significant and ever-increasing rate. While many brain-imaging agents, such as markers of amyloid-beta in dementia, are studied with the ultimate goal of application to clinical prognostication and differential diagnosis, other agents are fundamental research tools for understanding new drugs, such as antipsychotics, antidepressants, and anxiolytics, as well as drugs for the relief of devastating neurological disorders such as multiple sclerosis, stroke, and dementia. Some of the earliest markers were tracers of blood flow used with autoradiography, SPECT, and PET, but in 1977, Sokoloff et al. published the seminal description of the use of labeled 2-deoxyglucose to trace the rate of glucose phosphorylation in brain, initially by autoradiography but soon after also by positron emission tomography of the brain uptake of the glucose analog 2-fluoro-2-deoxyglucose, labeled with the positron emitter fluorine-18 (FDG). The basis for the use of this tracer ex as well as in vivo is a deceptively simple model of brain glucose metabolism that includes only the steps of the bidirectional transport of glucose and glucose analogs across the blood-brain barrier imposed by the tight junctions between the endothelial cells of the brain’s capillaries, and the step of phosphorylation enabled by the presence of the enzyme hexokinase in the cells of the brain.
This chapter provides a brief explanation of the quantitative method of PET imaging with FDG used by neuroscientists for the last 40 years to quantify the uptake and metabolism of this tracer in terms of the absolute rate of glucose phosphorylation in brain tissue during the period following the tracer administration. The chapter also highlights the issues of relative precision and accuracy of the method applied to high-resolution research tomography. It includes a description of the basic elements of quantification, and, in particular, of the necessary mathematical modeling of the dynamic brain records of the uptake of the tracer, both to justify the role of such modeling in study design and to validate some of the simplifications that are necessary in some clinical settings. As fundamental tools of neuroimaging, quantification and kinetic modeling are as important as image reconstruction and structural identification of regions of interest. The quantitative methods presented here continue to underpin the routine approaches to measures of brain glucose consumption rates in different regions of the brain and hence matter to most clinicians and clinician scientists involved in the neuroimaging practice of regional glucose phosphorylation rates.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- CBF:
-
Cerebral blood flow
- CMRglc :
-
Cerebral metabolic rate of glucose
- CMRO2 :
-
Cerebral metabolic rate of oxygen
- FDG:
-
[18F]fluorodeoxyglucose
- GLUT:
-
Glucose transporter
- HRRT:
-
High-resolution research tomograph
- LC:
-
Lumped constant
- MRI:
-
(Nuclear) magnetic resonance imaging
- PET:
-
Positron emission tomography
- ROI:
-
Region(s) of interest
- SPECT:
-
Single-photon emission computed tomography
- VOI:
-
Volume(s) of interest
References
Berti V et al (2013) Back to the future: the absolute quantification of cerebral metabolic rate of glucose. Clin Transl Imaging. doi:10.1007/s40336-013-0030-2
Gjedde A, Bauer B, Wong DF (2011) Neurokinetics: the dynamics of neurobiology in vivo. Springer, New York
Gjedde A (2008) Functional brain imaging celebrates 30th anniversary. Acta Neurol Scand 117(4):219–223
Gjedde A (1980) Rapid steady-state analysis of blood-brain glucose transfer in rat. Acta Physiol Scand 108(4):331–339
Sokoloff L et al (1977) The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28(5):897–916
Reivich M et al (1979) The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 44(1):127–137
Gjedde A (1982) Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination. Brain Res 257(2):237–274
Gjedde A et al (1985) Comparative regional analysis of 2-fluorodeoxyglucose and methylglucose uptake in brain of four stroke patients. With special reference to the regional estimation of the lumped constant. J Cereb Blood Flow Metab 5(2):163–178
Hasselbalch SG et al (2001) The [18F]fluorodeoxyglucose lumped constant determined in human brain from extraction fractions of [18F]F-fluorodeoxyglucose and glucose. J Cereb Blood Flow Metab 21(8):995–1002
Bass L et al (2011) Analogue tracers and lumped constant in capillary beds. J Theor Biol 285(1):177–781
Kuwabara H, Evans AC, Gjedde A (1990) Michaelis-Menten constraints improved cerebral glucose metabolism and regional lumped constant measurements with [18F]fluorodeoxyglucose. J Cereb Blood Flow Metab 10(2):180–189
Kuwabara H, Gjedde A (1991) Measurements of glucose phosphorylation with FDG and PET are not reduced by dephosphorylation of FDG-6-phosphate. J Nucl Med 32: 692–698
Kuikka JT et al (1991) Mathematical modelling in nuclear medicine. Eur J Nucl Med 18:351–362
Sheppard CW (1948) The theory of the study of transfers within a multi-compartment system. J Appl Phys 19(70)
Rescigno A, Beck J (1972) Compartments. In: Rosen R (ed) Foundations of mathematical biology, 1st edn. Academic, New York, pp 255–322
Rescigno A, Beck J (1987) The use and abuse of models. J Pharmacokinet Biopharm 15: 327–344
Ghosh A, Cheung YY, Mansfield BC, Chou JY (2005) Brain contains a functional glucose-6-phosphatase complex capable of endogenous glucose production. J Biol Chem 280: 11114–11119
Gejl M, Lerche S, Egefjord L, Brock B, Møller N, Vang K, Rodell AB, Bibby BM, Holst JJ, Rungby J, Gjedde A (2013) Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain. Front Neuroenergetics 5:2. doi:10.3389/fnene.2013.00002. eCollection 2013
Gjedde A (1981) High- and low-affinity transport of D-glucose from blood to brain. J Neurochem 36(4):1463–1471
Acknowledgements
Danish National Science Foundation Center of Excellence grants 2001 and 2006, Global Excellence Award 2010, Capital Region, Denmark.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Gjedde, A. (2014). Positron Emission Tomography of Brain Glucose Metabolism with [18F]Fluorodeoxyglucose in Humans. In: Hirrlinger, J., Waagepetersen, H. (eds) Brain Energy Metabolism. Neuromethods, vol 90. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1059-5_14
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1059-5_14
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-1058-8
Online ISBN: 978-1-4939-1059-5
eBook Packages: Springer Protocols